Remi Barbier and the Alzheimer’s Drug Controversy That Shook Biotech
When Remi Barbier stood before investors promising a new approach to Alzheimer’s disease, Cassava Sciences looked like one of the most unlikely success stories in biotech. The Texas-based company, once a struggling